We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
57 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir (as sodium) 30 mg film coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial.
-
Australian Public Assessment Report (AusPAR)AusPAR for Apretude (cabotegravir) for the prevention (to reduce the risk) of sexually acquired HIV-1 infection.
-
Cancellation by sponsorRequested by ViiV Healthcare Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TIVICAY PD dolutegravir (as sodium) 5 mg dispersible tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RUKOBIA fostemsavir (as trometamol) 600 mg extended release tablet bottle.
-
Prescription medicine registrationActive ingredients: cabotegravir sodium, cabotegravir.
-
Australian Public Assessment Report (AusPAR)TIVICAY (dolutegravir ) for treatment of HIV infection in combination with other antiretroviral agents.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CABENUVA cabotegravir 600 mg/3 mL plus rilpivirine 900 mg/3 mL prolonged-release suspensions for injection vials.